PharMerica CORP Form 8-K February 09, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 9, 2012

PHARMERICA CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-33380 (Commission File Number) 87-0792558 (IRS Employer Identification No.)

1901 Campus Place Louisville, Kentucky 40299 (Address of principal executive offices) (Zip Code)

(502) 627-7000 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02

Results of Operations and Financial Condition.

On February 9, 2012, PharMerica Corporation (the "Company") issued a press release announcing results of operations for the fourth quarter and year ended December 31, 2011, a copy of which is attached as Exhibit 99.1

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

99.1

Press Release of PharMerica Corporation dated February 9, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMERICA CORPORATION

Date: February 9, 2012 By: /s/ Michael J. Culotta

Michael J. Culotta

Executive Vice President and Chief Financial

Officer

Exhibit Index

Exhibit No. Description

99.1 Press Release of PharMerica Corporation dated February 9, 2012.